NCT07738107RecruitingPhase 1/2
ATR 1072 in Participants With PRKAG2 Syndrome
A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous ATR 1072 for the Treatment of PRKAG2 Syndrome
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- First submitted
- 26 Jun 2026
- Start date
- 14 Sept 2026
- Primary completion date
- May 2028
- Lead sponsor
- Atrium Therapeutics
- Diseases
- Parkinson disease
- NCT number
- NCT07738107
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 37
- From 14 Sept 2026 to the primary completion date, May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods.
Other illness
- Any condition that, in the investigator's
Lab values
- NYHA Class IV heart failure or left ventricular ejection fraction \<45%.
Other
- Pregnancy or breastfeeding.
- Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.
- Recent clinically significant cardiovascular events or procedures.
Who the study is looking for
- Adults 18 to 65 years of age.
- Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.
- Clinical manifestations consistent with PRKAG2 Syndrome.
- Able and willing to comply with study procedures.
- Able and willing to undergo endomyocardial biopsy procedures (Part A)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St Luke's Mid American Heart Institute Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.